<!DOCTYPE html>
<html lang="no">
<head>
	<meta charset="iso-8859-1">
	<title>Norsk legemiddelh&aring;ndbok - L2.2</title>
	<link rel="shortcut icon" href="../favicon.ico" type="image/x-icon">
	<script type="text/javascript" src="../js/default.js"></script>
	<link href="../css/default.css" rel="stylesheet"  media="screen" type="text/css"/>
	<link href="../css/print.css" rel="stylesheet"  media="print" type="text/css"/>
	<!--[if lt IE 9]><link href="../css/ieless9.css" rel="stylesheet" type="text/css"/><![endif]-->
	<script>
	jQuery(function($) {
		
		var setMenues = function(){
			if(menu){
				$('#navTerapi').append(menu[0]);
				$('#navLegemiddel').append(menu[1]);
				$('#navGenerel').append(menu[2]);
			}
		}		

	
		$(document).ready(function() {
			setMenues();
		});
	});

	</script>
</head>
<body>
<div id="mainframe">
	<header>
		<img src="gfx/logo_print.png" />
		<a href="../index.htm"><h1>Norsk legemiddelh&aring;ndbok</h1></a>
		<form id="search" name="searchForm" action="sok/sokresultat.htm">
            <input type="text" name="searchField" size="30" placeholder="Fritekstsøk">
	        <input type="hidden" name="srcriteria" value="all"><br>
            <button type="submit">Søk</button>
	    </form>
	    	<nav>
			<ul>
				<li id="navTerapi"><a href="../T/innhold.htm">Terapikapitler</a></li>
				<li id="navLegemiddel"><a href="innhold.htm">Legemiddelkapitler</a></li>
				<li id="navGenerel"><a href="../G/innhold.htm">Generelle kapitler</a></li>
				<li id="navStikkord"><a href="../div/stikkordA.htm">Stikkord</a></li>
				<!-- li id="navAkutt"><a href="../div/hastebehandling.htm">Hastebehandling</a></li -->
			</ul>
		</nav>
	</header>
	<div id="bodyframe">
	
<nav><div id="menu"><ul>
<li><a href="L2.2.htm#i41965">L2.2.1&nbsp;Deksrazoksan</a>
</li><li><a href="L2.2.htm#i42006">L2.2.2&nbsp;Mesna</a>
</li><li><a href="L2.2.htm#i42042">L2.2.3&nbsp;Rasburikase</a>
</li></ul></div>
</nav>
<article id="content" >
<div id="i41963" class="seksjon2"><h2  style='color:blue' id="i41964">L2.2&nbsp;Midler som motvirker toksisitet av cytostatika</h2>
<div id="i253646" class="revidert">
<p class="reviderta"><p id="i253647">Publisert: 20.06.2010</p></p></div><div id="i41965" class="seksjon3"><h3  style='color:blue' id="i41966">L2.2.1&nbsp;Deksrazoksan</h3>
<div id="i253668" class="revidert">
<p class="reviderta"><p id="i253669">Publisert: 20.06.2010</p></p>
<p class="reviderta"><p id="i316708">Sist endret: 25.10.2012</p></p></div><div id="i41967" class="def"><h5  id="i41968">Egenskaper</h5>

<p class="defa"><p id="i41969">Deksrazoksan motvirker veksthemmende effekter og DNA-skade indusert av antrasykliner og antracendioner. Deksrazoksan er en EDTA-analog som lett penetrerer cellemembraner. Intracellulært hydrolyseres deksrazoksan til ADR-925 som er en kraftig kelator for jern og toverdige kationer. ADR-925 kelaterer jern, fjerner jern fra jernantrasyklinkomplekset eller binder jern i cellen og reduserer derved dannelse av ødeleggende reaktive oksygenradikaler. Topoisomerase II vil også hemmes, men i motsetning til ved antrasykliner induseres ikke kjedebrudd i DNA.</p></p></div><div id="i41970" class="def"><h5  id="i41971">Farmakokinetikk</h5>

<p class="defa"><p id="i41972">Deksrazoksan har en  terminal eliminasjonshalveringstid på 2&#x2013;9 timer. Ekskresjonen skjer  hovedsakelig i nyrene, 40&#x2013;60 % av total mengde deksrazoksan skilles uendret  ut i urinen.</p></p></div><div id="i41973" class="def"><h5  id="i41974">Indikasjoner</h5>

<p class="defa"><p id="i41975">Deksrazoksan brukes til behandling av ekstravasasjon av antrasyklin. Det er også vist beskyttende effekt av deksrazoksan mot antrasyklinindusert kardiotoksisitet, men verdien av denne behandlingen er ennå ikke klarlagt.</p></p></div><div id="i41976" class="def"><h5  id="i41977">Dosering og administrasjon</h5>

<p class="defa"><p id="i41978">Anbefalt dose er 1000 mg/m<Sup>2</Sup> kroppsoverflate  som intravenøs infusjon gitt over 1&#x2013;2 timer dag 1 og 2, og 500 mg/m<Sup>2</Sup> som  intravenøs infusjon gitt over 1&#x2013;2 timer dag 3. Første infusjon skal  startes så raskt som mulig og innen 6 timer etter ekstravasasjon.  Infusjonen skal gis i en stor vene i en ekstremitet eller et område  som ikke er påvirket av ekstravasasjonen.</p></p></div><div id="i41979" class="def"><h5  id="i41980">Bivirkninger</h5>

<p class="defa"><p id="i41981">Vanlige bivirkninger  er kvalme/oppkast, diaré, stomatitt og beinmargsdepresjon. Påvirket  leverfunksjon (forhøyet ALAT/ASAT) forekommer også. Samtlige bivirkninger  er raskt reversible.</p></p></div><div id="i41982" class="def"><h5  id="i41983">Graviditet, amming</h5>

<p class="defa"><p id="i41984">Erfaring med bruk hos  gravide mangler. Dyreforsøk har vist teratogen effekt. Brukes som  del av cytostatikabehandling hvor amming er kontrindisert.</p></p></div><div id="i41985" class="def"><h5  id="i41986">Forsiktighetsregler</h5>

<p class="defa"><p id="i41987">Da nedsatt nyrefunksjon  kan redusere eliminasjonshastigheten for deksrazoksan, bør pasienter  med allerede svekket nyrefunksjon overvåkes for tegn på hematologisk  toksisitet.</p></p></div><div id="i41988" class="def"><h5  id="i41989">Kontroll og oppfølging</h5>

<p class="defa"><p id="i41990">Deksrazoksan kan øke  toksisiteten indusert av den kjemoterapisyklusen som pågikk da uhellet  skjedde, noe som krever nøye overvåking av hematologiske parametre.</p></p></div><div id="i41991" class="def"><h5  id="i41992">Informasjon til pasient</h5>

<p class="defa"><p id="i41993">Bivirkninger.</p></p></div>
<div class="boks"><div id="i41994" class="box"><h5  id="i41995">Deksrazoksan</h5>

<p class="boxa"><p id="i41996"><strong>Rp. C</strong> </p></p><div id="i41997" class="sub-box"><h6  id="i41998">Savene</h6>

<p class="sub-boxa"><p id="i41999">«SpePharm»</p></p>	<UL type="circle">
		<LI id="i42001"><p id="i42002"><strong>infusjonssubstans</strong> <em>500 mg.</em> 10 hetteglass: kr  &nbsp; (Trinnpris kr ).</p><br>		</LI>
	</UL>
</div></div></div><div id="i42003" class="tone-kilde"><h6  id="i42004">Kilder.</h6>

<p class="tone-kildea"><p id="i42005">Deksrazoksan  <a id="aSeksjon1X38346" class="ref" href="../L/L2.htm#i4215138346" title="Deksrazoksan">Deksrazoksan</a>.</p></p></div></div><div id="i42006" class="seksjon3"><h3  style='color:blue' id="i42007">L2.2.2&nbsp;Mesna</h3>
<div id="i253670" class="revidert">
<p class="reviderta"><p id="i253671">Publisert: 20.06.2010</p></p></div><div id="i42008" class="def"><h5  id="i42009">Egenskaper</h5>

<p class="defa"><p id="i42010">Mesna (2&#8209;merkaptoetansulfonat) er en sulfhydrylforbindelse som konsentreres i urinen og beskytter mot de toksiske virkningene i de nedre urinveiene av metabolitter (særlig akrolein) av syklofosfamid og ifosfamid. Har bare beskjeden og kortvarig beskyttende effekt mot nyreskade. Synes ikke å svekke den cytostatiske effekten av syklofosfamid/ifosfamid.</p></p></div><div id="i42011" class="def"><h5  id="i42012">Farmakokinetikk</h5>

<p class="defa"><p id="i42013">Mesna metaboliseres raskt  og nesten fullstendig i blodet ved oksydering til inaktiv metabolitt,  dimesna. Denne utskilles, men reabsorberes delvis i nyretubuli og  spaltes der via glutation reduktase til aktivt mesna. Utskilles  hovedsakelig via nyrene. Halveringstiden for mesna er ca. 20 minutter  og for dimesna 1&#x2013;2 timer.</p></p></div><div id="i42014" class="def"><h5  id="i42015">Indikasjoner</h5>

<p class="defa"><p id="i42016">Forebyggende mot nedre urinveisskade av ifosfamid eller syklofosfamid. Skal gis til alle som får ifosfamid, pasienter som får syklofosfamid i høy dosering, dem som tidligere har fått cystitt ved behandling med syklofosfamid og dessuten til dem som har fått strålebehandling mot lille bekken eller har hatt urinveisobstruksjon tidligere.</p></p></div><div id="i42017" class="def"><h5  id="i42018">Dosering og administrasjon</h5>

<p class="defa"><p id="i42019">Mesna gis oftest intravenøst i tilslutning til administrasjonen av ifosfamid eller høye doser syklofosfamid. Det må tilføres hyppig, f.eks. ca. hver 4. time, og gis fra ca. 0,5 time før til ca. 12 timer etter ifosfamid eller syklofosfamid. Den totale dosen er ofte ca. 60 % av ifosfamiddosen (se spesiallitteratur).</p></p></div><div id="i42020" class="def"><h5  id="i42021">Bivirkninger</h5>

<p class="defa"><p id="i42022">Vanlig forekommende: kvalme,  brekninger, diaré. Hypotensjon. Hudkløe. Sjeldne: allergiske reaksjoner.</p></p></div><div id="i42023" class="def"><h5  id="i42024">Graviditet, amming</h5>

<p class="defa"><p id="i42025">Erfaring med bruk hos  gravide er begrenset. Opplysninger mangler om bruk under amming.</p></p></div><div id="i42026" class="def"><h5  id="i42027">Kontraindikasjoner</h5>

<p class="defa"><p id="i42028">Overfølsomhet for mesna  og andre tiolforbindelser.</p></p></div>
<div class="boks"><div id="i42029" class="box"><h5  id="i42030">Mesna</h5>

<p class="boxa"><p id="i42031"><strong>Rp. C</strong>  </p></p><div id="i42032" class="sub-box"><h6  id="i42033">Uromitexan</h6>

<p class="sub-boxa"><p id="i42034">«Baxter Oncology»</p></p>	<UL type="circle">
		<LI id="i42036"><p id="i42037"><strong>injeksjonsvæske</strong> <em>100 mg/ml.</em> 15 <Spesfont Font = "Symbol">x </Spesfont>4 ml kr &nbsp;436,50, 10 <Spesfont Font = "Symbol">x</Spesfont> 10 ml kr &nbsp;704,20.</p><br>		</LI>
		<LI id="i42038"><p id="i42039"><strong>tabletter</strong> <em>400 mg.</em> 10 stk.  (enpac) kr &nbsp;329,00, 20 stk. (enpac) kr &nbsp;622,90.</p><br>		</LI>
		<LI id="i42040"><p id="i42041"><strong>tabletter</strong> <em>600 mg.</em> 10 stk.  (enpac) kr &nbsp;379,10, 20 stk. (enpac) kr &nbsp;723,30.</p><br>		</LI>
	</UL>
</div></div></div></div><div id="i42042" class="seksjon3"><h3  style='color:blue' id="i42043">L2.2.3&nbsp;Rasburikase</h3>
<div id="i253672" class="revidert">
<p class="reviderta"><p id="i253673">Publisert: 20.06.2010</p></p></div><div id="i42044" class="def"><h5  id="i42045">Egenskaper</h5>

<p class="defa"><p id="i42046">Rasburikase  er et enzym som katalyserer omdannelsen av urinsyre, som er produkt  av purinnedbrytning, til allantoin. Allantoin er vannløselig og  skilles lett ut via nyrene. Ved tilførsel av rasburikase kan dermed  opphopningen av urinsyre og risikoen for hyperuremiske komplikasjoner,  særlig nyresvikt, unngås ved tilstander med stor nedbrytning av  maligne celler. Rasburikase virker raskt og gir vanligvis normalisering  av urinsyrenivået innen 4 timer.</p></p></div><div id="i42047" class="def"><h5  id="i42048">Farmakokinetikk</h5>

<p class="defa"><p id="i42049">Metaboliseres sannsynligvis  som andre proteiner, f.eks. ved peptidhydrolyse. Halveringstiden  er 16&#x2013;21 timer.</p></p></div><div id="i42050" class="def"><h5  id="i42051">Indikasjoner</h5>

<p class="defa"><p id="i42052">Behandling  og profylakse mot akutt hyperurikemi, for å forhindre akutt nyresvikt  hos pasienter med hematologisk malignitet med høy tumorbelastning  og risiko for rask nedbrytning av tumorceller når kjemoterapi startes.</p></p></div><div id="i42053" class="def"><h5  id="i42054">Dosering  og administrasjon</h5>

<p class="defa"><p id="i42055">Vanligvis 0,2 mg/kg/dag  i 5&#x2013;7 dager, gitt som intravenøs infusjon. Se spesiallitteratur.</p></p></div><div id="i42056" class="def"><h5  id="i42057">Bivirkninger</h5>

<p class="defa"><p id="i42058">Allergiske  reaksjoner forekommer. Methemoglobinemi og hemolyse er rapportert,  og er trolig resultat av H<Sub>2</Sub>O<Sub>2</Sub> som produseres  ved den enzymatiske omdannelsen av urinsyre til allantoin. Dette  forekommer meget sjelden, hos disponerte pasienter (G6PD-mangel).</p></p></div><div id="i42059" class="def"><h5  id="i42060">Graviditet,  amming</h5>

<p class="defa"><p id="i42061">Opplysninger  mangler om bruk under graviditet og amming.</p></p></div><div id="i42062" class="def"><h5  id="i42063">Forsiktighetsregler</h5>

<p class="defa"><p id="i42064">Vær oppmerksom  på muligheten for allergiske reaksjoner, særlig hos personer med  atopi.</p></p></div>
<div class="boks"><div id="i42065" class="box"><h5  id="i42066">Rasburikase</h5>

<p class="boxa"><p id="i42067"><strong>Rp. C</strong>  </p></p><div id="i42068" class="sub-box"><h6  id="i42069">Fasturtec</h6>

<p class="sub-boxa"><p id="i42070">«Sanofi-Synthelabo»</p></p>	<UL type="circle">
		<LI id="i42072"><p id="i42073"><strong>injeksjonssubstans</strong> <em>1,5 mg.</em> Ampuller:  3 stk. kr &nbsp;2&nbsp;416,90.</p><br>		</LI>
	</UL>
</div></div></div><div id="i42074" class="tone-kilde"><h6  id="i42075">Kilder.</h6>

<p class="tone-kildea"><p id="i42076">Legemidler i behandlingen av kreftsykdommer  <a id="aSeksjon1X38346" class="ref" href="../L/L2.htm#i4208038346" title="Legemidler i behandlingen  av kreftsykdommer">Legemidler i behandlingen  av kreftsykdommer</a>.</p></p></div></div></div><div id="i42077" class="kilder"><h5  id="i42078">Kilder</h5>
<div id="i42079" class="altsek1"><h1  id="i42080">Legemidler i behandlingen  av kreftsykdommer</h1>

<p class="altsek1a"><p id="i42081">Adams VR, Leggas M (2007): Sunitinib  malate for the treatment of metastatic renal cell carcinoma an gastrointestinal  stromal tumors. Clin Ther. 29, 1338-1353.</p></p>
<p class="altsek1a"><p id="i42082">Andersson BS, Madden T, Tran HT, Hu  WW, Blume KG, Chow DS, Champlin RE, Vaughan WP (2000): Acute safety  and pharmacokinetics of intravenous busulfan when used with oral  busulfan and cyclophosphamide as pretransplantation conditioning  therapy: a phase I study. Biol Blood Marrow Transplant. 6, 548-554.</p></p>
<p class="altsek1a"><p id="i42083">Bareschino MA, Schettino C, Troiani  T, Martinelli E, Morgillo F, Ciardiello F (2007): Erlotinib in cancer  treatment. Ann Oncol. 18, vi35-vi41. </p></p>
<p class="altsek1a"><p id="i42084">Beasley GM, Ross MI, Tyler DS (2008):  Future directions in regional treatment strategies for melanoma  and sarcoma. Int J Hypothermia 24, 301-309.</p></p>
<p class="altsek1a"><p id="i42085">Bennouna J, Delord JP, Campone M, Nguyen  L (2008): Vinflunine: a new microtubule inhibitor agent. Clin Cancer  Res. 14, 1625-1632.</p></p>
<p class="altsek1a"><p id="i42086">Berman E (1992): New drugs in acute  myelogenous leukemia: a review. J Clin Pharmacol. 32, 296&#x2013;309.</p></p>
<p class="altsek1a"><p id="i42087">Bertino P, Piccardi F, Porta C. Favoni  R, Cilli M, Mutti L, Gaudino G (2008): Imatinib mesylate enhances  therapeutic effects of gemcitabine in human malignant mesothelioma  xenografts. Clin Cancer Res. 14, 541-548.</p></p>
<p class="altsek1a"><p id="i42088">Buesa JM, Urrechaga E (1991): Clinical  pharmacokinetics of high-dose DTIC. Cancer Chemother Pharmacol.  28, 475-479.</p></p>
<p class="altsek1a"><p id="i42089">Buie LW, Epstein SS, Lindley CM (2007):  Nelarabine: a novel purine antimetabolite antineoplastic agent.  Clin Ther. 29, 1887-1899.</p></p>
<p class="altsek1a"><p id="i42090">Cai H, Wang Q, Luo J, Lim CK (1999):  Study of temoporfin metabolism by HPLC and electrospray mass spectrometry.  Biomed Chromatogr. 13, 354-359. </p></p>
<p class="altsek1a"><p id="i42091">Carter NJ, Keam SJ (2007): Trabectedin:  a review of its use in the management of soft tissue sarcoma and  ovarian cancer. Drugs 67, 2257-2276.</p></p>
<p class="altsek1a"><p id="i42092">Chang TK, Yu L, Goldstein JA, Waxman  DJ (1997): Identification of the polymorphically expressed CYP2C19  and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide  and ifosfamide activation. Pharmacogenetics 7, 211-221.</p></p>
<p class="altsek1a"><p id="i42093">Chattopadhyay S, Moran RG, Goldman ID  (2007): Pemetrexed: biomedical and cellular pharmacology, mechanisms,  and clinical applications. Mol Cancer Ther. 6, 404-417.</p></p>
<p class="altsek1a"><p id="i42094">Chen N, Lau H, Kong L, Kumar G, Zeldis  JB, Knight R, Laskin OL (2007): Pharmacokinetics of lenalidomide  in subjects with various degrees of renal impairment and in subjects with  hemodialysis. J Clin Pharmacol. 47, 1466-1475.</p></p>
<p class="altsek1a"><p id="i42095">Cheson BD, Dutcher BS (2005): Managing  malignancy-associated hyperuricemia with rasburicase. J Support  Oncol. 3, 117-124</p></p>
<p class="altsek1a"><p id="i42096">Choueiri TK, Alemany CA, Abou-Jawde  RM, Budd GT (2004): Role of aromatase inhibitors in the treatment  of breast cancer. Clin Ther. 26, 1199-1214. </p></p>
<p class="altsek1a"><p id="i42097">Curbo S, Karlsson A (2006): Nelarabine:  a new purine analog in the treatment of hematologic malignancies.  Rev Recent Clin Trials 1, 185-192.</p></p>
<p class="altsek1a"><p id="i42098">Curran MP, Croom KF, Goa KL (2004):  Spotlight on imatinib mesylate in chronic myeloid leukemia. BioDrugs 18,  207-210.</p></p>
<p class="altsek1a"><p id="i42099">Dahl O, Lehne G, Baksaas I, Kvaløy S,  Christoffersen T (red.): Medikamentell kreftbehandling. Cytostatikaboken  7. utg. 2009. Farmakologisk Institutt, Det medisinske fakultet,  Universitetet i Oslo.</p></p>
<p class="altsek1a"><p id="i42100">Deininger MW (2008): Nilotinib. Clin  Cancer Res. 14, 4027-4031.</p></p>
<p class="altsek1a"><p id="i42101">DeRemer DL, Ustun C, Natarajan K (2008):  Nilotinib: a second-generation tyrosine kinase inhibitor for the  treatment of chronic myelogenous leukemia. Clin Ter. 30, 1956-1975.</p></p>
<p class="altsek1a"><p id="i42102">Desoize B, Madoulet C (2002): Particular  aspects of platinum compounds used at present in cancer treatment.  Crit Rev Oncol Hematol. 42, 317-325.</p></p>
<p class="altsek1a"><p id="i42103">Falco P, Cavallo F, Larocca A, Liberati  AM, Musto P, Boccadoro M, Palumbo A (2008): Lenalidomide and its  role in the management of multiple myeloma. Expert Rev Anticancer Ther.  8, 865-874.</p></p>
<p class="altsek1a"><p id="i42104">Fleming RA (1997): An overview of cyclophosphamide  and ifosfamide pharmacology. Pharmacotherapy 17,146S-154S.</p></p>
<p class="altsek1a"><p id="i42105">Gebbia V, Puozzo C (2005): Oral versus  intravenous vinorelbine: clinical safety profile. Expert Opin Drug  Saf. 4, 915-928.</p></p>
<p class="altsek1a"><p id="i42106">Gillis JC, Goa KL (1995): Tretinoin.  A review of its pharmacodynamic and pharmacokinetic properties and  use in the management of acute promyelocytic leukemia. Drugs 50,  897-923.</p></p>
<p class="altsek1a"><p id="i42107">Gwilt PR,Tracewell WG (1998): Pharmacokinetics  and pharmacodynamics of hydroxyurea. Clin Pharmacokinet. 34, 347-358.</p></p>
<p class="altsek1a"><p id="i42108">Hartmann JT, Lipp HP (2006): Camptothecin  and podophyllotoxin derivatives: inhibitors of topoisomerase I and  II - mechanisms of action, pharmacokinetics and toxicity profile. Drug  Saf. 29, 209-230.</p></p>
<p class="altsek1a"><p id="i42109">Hartmann JT, Haap M, Kopp HG, Lipp HP  (2009): Tyrosine kinase inhibitors - a review on pharmacology, metabolism  and side effects. Curr Drug Metab. 10, 470-481.</p></p>
<p class="altsek1a"><p id="i42110">Holte H, Smeland S, Blystad AK, Kvaløy  S, Hammerstrøm J, Tjønnfjord GE (2002): Intensiv kjemoterapi ved  Burkitts lymfom og aggressivt non-Hodgkins lymfom.Tidsskr Nor Legeforen.  122, 364-369.</p></p>
<p class="altsek1a"><p id="i42111">Houle JM, Clervoix N, Bain S, Spénard  J (2006): Lack of effect of sex and disease state on the pharmacokinetics  of porfimer sodium. Clin Pharmacokinet- 45, 923-930.</p></p>
<p class="altsek1a"><p id="i42112">Issa JPJ, Kantarjian HM, Kirkpatrick  P (2005): Azacitidine. Nature Rev Drug Discovery 4, 275-276.</p></p>
<p class="altsek1a"><p id="i42113">James CA, Mant TG, Rogers HJ (1987):  Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane  sulphonate (mesna) in normal subjects. Br J Clin Pharmacol- 23,  561-568.</p></p>
<p class="altsek1a"><p id="i42114">Jones RJ (2008): Utility of dexrazoxane  for the reduction of anthracycline-induced cardiotoxicity. Expert  Rev Cardiovasc Ther- 6, 1311-1317.</p></p>
<p class="altsek1a"><p id="i42115">Jurlina JL, Varcoe AR, Paxton JW (1985):  Pharmacokinetics of amsacrine in patients receiving combined chemotherapy  for treatment of acute myelogenous leukemia. Cancer Chemother Pharmacol-  14, 21-25.</p></p>
<p class="altsek1a"><p id="i42116">Kitamura T (2001): Necessity of re-evaluation  of estramustine phosphate sodium (EMP) as a treatment option for  first-line monotherapy in advanced prostate cancer. Int J Urol.  8, 33-36.</p></p>
<p class="altsek1a"><p id="i42117">Kumar S, Rajkumar SV (2006): Thalidomide  and lenalidomide in the treatment of multiple myeloma. Eur J Cancer  42, 1612-1622.</p></p>
<p class="altsek1a"><p id="i42118">Langer SW (2007): Dexrazoxane for anthracycline  extravasation. Expert Rev Anticancer Ther. 7, 1081-1088.</p></p>
<p class="altsek1a"><p id="i42119">Lobert S, Puozzo C (2008): Pharmacokinetics,  metabolites, and preclinical safety of vinflunine. Semin Oncol 35  (Suppl 3), S28-S33.</p></p>
<p class="altsek1a"><p id="i42120">Narta UK, Kanwar SS, Azmi W (2007):  Pharmacological and clinical evaluation of L-asparaginase in the  treatment of leukemia. Crit Rev Oncol Hematol. 61, 208-221.</p></p>
<p class="altsek1a"><p id="i42121">Petrides PE, Gisslinger H, Steurer M,  Linkesch W, Krumpl G, Schüller A, Widmann R (2009): Pharmacokinetics,  bioequivalence, tolerability, and effects on platelet counts of  two formulations of anagrelide in healthy volunteers and patients  with thrombocythemia associated with chronic myeloproliferation.  Clin Ther. 31, 386-398. </p></p>
<p class="altsek1a"><p id="i42122">Reck M (2009): Gefitinib in the treatment  of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther.  9, 401-412.</p></p>
<p class="altsek1a"><p id="i42123">Reigner B, Blesch K, Weidekamm E (2001):  Clinical pharmaokinetics of capecitabine. Clin Pharmacokinet. 40,  85-104.</p></p>
<p class="altsek1a"><p id="i42124">Ricciardi S, Tomao A, de Marinis F (2009):  Toxicity of targeted therapy in non-small-cell lung cancer management.  Clin Lung Cancer 10, 28-35.</p></p>
<p class="altsek1a"><p id="i42125">Sanford M, Plosker GL (2008): Anastrozole:  a review of its use in postmenopausal women with early-stage breast  cancer. Drugs 68, 1319-1340.</p></p>
<p class="altsek1a"><p id="i42126">Sanford M, Lyseng-Williamson KA (2008):  Nelarabine. Drugs 68, 439-447.</p></p>
<p class="altsek1a"><p id="i42127">Schteingart DE (2007): Adjuvant mitotane  therapy of adrenal cancer - use and controversy. N Engl J Med. 356,  2415-2418. </p></p>
<p class="altsek1a"><p id="i42128">Schwartz R, Davidson T (2004): Pharmacology,  pharmacokinetics, and practical applications of bortezomib. Oncology  18, 14-21.</p></p>
<p class="altsek1a"><p id="i42129">Scripture CD, Sparreboom A, Figg WD  (2005): Modulation of cytochrome P450 activity: implications for  cancer therapy. Lancet Oncol. 6, 780-789.</p></p>
<p class="altsek1a"><p id="i42130">Siddiqui MAA, Scott LJ (2005): Azacitidine  in myelodysplastic syndromes. Drugs 65, 1781-1789.</p></p>
<p class="altsek1a"><p id="i42131">Spratlin J, Sawyer MB (2007): Pharmacogenetics  of paclitaxel metabolim. Crit Rev Oncol Hematol. 61, 222-229.</p></p>
<p class="altsek1a"><p id="i42132">Strumberg D, Clark JW, Awada A, Moore  MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B  (2007): Safety, pharmacokinetics, and preliminary antitumor activity of  sorafenib: a review of four phase I trials in patinets with advanced  refractory solid tumors. Oncologist 12, 426-437. </p></p>
<p class="altsek1a"><p id="i42133">Triesscheijn M, Ruevekamp M, Out R,  Van Berkel TJ, Schellens J, Baas P, Stewart FA (2007): The pharmacokinetic  behavior of the photosensitizer meso-tetra-heydroxyphenylchlorin  in mice and men. Cancer Chemother Pharmacol. 60, 113-122.</p></p>
<p class="altsek1a"><p id="i42134">van Schaik RH (2008): CYP450 pharmacogenetics  for peronalizing cancer therapy. Drug Resist Updat. 11, 77-98.</p></p>
<p class="altsek1a"><p id="i42135">Verweij J, Pinedo HM (1990): Mitomycin  C: mechanism of action, usefulness and limitations. Anticancer Drugs 1,  5-13.</p></p>
<p class="altsek1a"><p id="i42136">Wilson J, Connock M, Song F, Yao G,  Fry-Smith A, Raftery J, Peake D (2005): Imatinib for the treatment  of patients with unresectable and/or metastatic gastrointestinal  stromal tumours: systematic review and economic evaluation. Health  Technol Assess. 9, 1-142.</p></p>
<p class="altsek1a"><p id="i42137">Yun-San Yip A, Yen-Yen Ong E, Chow LW  (2008): Vinflunine: clinical perspectives of an emerging anticancer  agent. Expert Opin Investig Drugs 17, 583-591.</p></p>
<p class="altsek1a"><p id="i42138">Preparatomtaler: www.legemiddelverket.no , www.ema.europa.eu , www.medicines.org.uk , www.medsafe.govt.nz , www.axcan.com</p></p></div><div id="i42139" class="altsek1"><h1  id="i42140">Azacitidin</h1>

<p class="altsek1a"><p id="i42141">Siddiqui MAA, Scott LJ (2005): Azacitidine  in myelodysplastic syndromes. Drugs 65, 1781-1789.</p></p>
<p class="altsek1a"><p id="i42142">Issa JPJ, Kantarjian HM, Kirkpatrick  P (2005): Azacitidine. Nature Rev Drug Discovery 4, 275-276.</p></p>
<p class="altsek1a"><p id="i42143">Preparatomtale Vidaza (www.legemiddelverket.no)</p></p></div><div id="i42144" class="altsek1"><h1  id="i42145">Dasatinib</h1>

<p class="altsek1a"><p id="i42146">McFarland KL, Wetzstein GA (2009):  Chronic myeloid leukemia therapy: Focus on second-generation tyrosine  kinase inhibitors. Cancer Control 16, 132-140</p></p>
<p class="altsek1a"><p id="i42147">Steinberg M (2007): Dasatinib: a tyrosine  kinase inhibitor for the treatment of chronic myelogenous leukemia  and philadelphia chromosome-positive acute lymphoblastic leukemia.  Clin Ther 29: 2289-2308.</p></p>
<p class="altsek1a"><p id="i42148">Preparatomtale Sprycel (<em>www.legemiddelverket.no</em>)</p></p>
<p class="altsek1a"><p id="i42149">Dahl, O., Lehne, G., Baksaas, I., Kvaløy,  S. & Christoffersen, T. (red.): Medikamentell kreftbehandling.  Cytostatikaboken 7. utg. Farmakologisk Institutt, Det medisinske  fakultet, Universitetet i Oslo.</p></p></div><div id="i42150" class="altsek1"><h1  id="i42151">Deksrazoksan</h1>

<p class="altsek1a"><p id="i42152">Langer SW (2007): Dexrazoxane for anthracycline  extravasation. Expert Rev Anticancer Ther 7:1081-1088.</p></p>
<p class="altsek1a"><p id="i42153">Jones RJ (2008): Utility of dexrazoxane  for the reduction of anthracycline-induced cardiotoxicity. Expert  Rev Cardiovasc Ther 6, 1311-1317.</p></p>
<p class="altsek1a"><p id="i42154">Preparatomtale Savene (<em>www.legemiddelverket.no</em>)</p></p>
<p class="altsek1a"><p id="i42155">Dahl, O., Lehne, G., Baksaas, I., Kvaløy,  S. & Christoffersen, T. (red.): Medikamentell kreftbehandling.  Cytostatikaboken 7. utg. Farmakologisk Institutt, Det medisinske  fakultet, Universitetet i Oslo.</p></p></div><div id="i42156" class="altsek1"><h1  id="i42157">Gefitinib</h1>

<p class="altsek1a"><p id="i42158">Reck M (2009) Exp Rev Anticancer Ther 9, 401-402.</p></p>
<p class="altsek1a"><p id="i42159">Hartmann JT, Haap M, KOpp HG, Lipp HP (2009) Curr Drug Metab 10. 470-481.</p></p>
<p class="altsek1a"><p id="i42160">Ricciardi, S, Tomao A, de Marinis F (2009) Clin Lung Cancer 10, 28-35.</p></p>
<p class="altsek1a"><p id="i42161">Preparatomtale <em>Iressa</em> (<em>www.ema.europa.eu</em>).</p></p>
<p class="altsek1a"><p id="i42162">Dahl, O., Lehne, G., Baksaas, I., Kvaløy, S. & Christoffersen, T. (red.): Medikamentell kreftbehandling. Cytostatikaboken 7. utg. Farmakologisk Institutt, Det medisinske fakultet, Universitetet i Oslo.</p></p></div><div id="i42163" class="altsek1"><h1  id="i42164">Klofarabin</h1>

<p class="altsek1a"><p id="i42165">Bonate PL, Arthaud L, Cantrell WR, Stephenson  K, Secrist JA, Weitman S (2006): Discovery and development of clofarabine:  a nucleoside analogue for treating cancer. Nat Rev Drug Discov 5,  855-863.</p></p>
<p class="altsek1a"><p id="i42166">Kantarjian HM, Jeha S, Gandhi V, Wess  M, Faderl S (2007): Clofarabine: past, present, and future. Leuk  Lymphoma 48, 1922-1930.</p></p>
<p class="altsek1a"><p id="i42167">Robak T, Korycka A, Lech-Maranda E,  Robak P (2009): Current status of older and new purine nucleoside  analogues in the treatment of lymphoproliferative diseases. Molecules  14, 1183-1226.</p></p>
<p class="altsek1a"><p id="i42168">Larson ML, Venugopal P (2009): Clofarabine:  a new treatment option for patients with acute myeloid leukemia.  Expert Opin Pharmacother 10, 1353-1357.</p></p>
<p class="altsek1a"><p id="i42169">Preparatomtale Evoltra (<em>www.legemiddelverket.no</em>)</p></p></div><div id="i42170" class="altsek1"><h1  id="i42171">Lapatinib</h1>

<p class="altsek1a"><p id="i42172">Medina PJ, Goodin S (2008): Lapatinib:  A dual inhibitor of human epidermal growth factor receptor tyrosine  kinases. Clin Ther 30, 1426-1447. </p></p>
<p class="altsek1a"><p id="i42173">Ulhoa-Cintra A, Greenberg L, Geyer CE  (2008): The emerging role of lapatinib in HER2-positive breast cancer.  Curr Oncol Rep 10, 10-17. </p></p>
<p class="altsek1a"><p id="i42174">Preparatomtale Atriance (<em>www.legemiddelverket.no</em>)</p></p>
<p class="altsek1a"><p id="i42175">Dahl, O., Lehne, G., Baksaas, I., Kvaløy,  S. & Christoffersen, T. (red.): Medikamentell kreftbehandling.  Cytostatikaboken 7. utg. Farmakologisk Institutt, Det medisinske  fakultet, Universitetet i Oslo.</p></p></div><div id="i42176" class="altsek1"><h1  id="i42177">Lenalidomid</h1>

<p class="altsek1a"><p id="i42178">Kumar S, Rajkumar SV (2006): Thalidomide  and lenalidomide in the treatment of multiple myeloma. Eur J Cancer  42, 1612-1622.</p></p>
<p class="altsek1a"><p id="i42179">Falco P, Cavallo F, Larocca A, Liberati  AM, Musto P, Boccadoro M, Palumbo A (2008): Lenalidomide and its  role in the management of multiple myeloma. Expert Rev Anticancer Ther  8, 865-874.</p></p>
<p class="altsek1a"><p id="i42180">Chen N, Lau H, Kong L, Kumar G, Zeldis  JB, Knight R, Laskin OL (2007): Pharmacokinetics of lenalidomide  in subjects with various degrees of renal impairment and in subjects  with hemodialysis. J Clin Pharmacol 47, 1466-1475.</p></p>
<p class="altsek1a"><p id="i42181">Preparatomtale Revlimid <em>(www.legemiddelverket.no</em>)</p></p>
<p class="altsek1a"><p id="i42182">Dahl, O., Lehne, G., Baksaas, I., Kvaløy,  S. & Christoffersen, T. (red.): Medikamentell kreftbehandling.  Cytostatikaboken 7. utg. Farmakologisk Institutt, Det medisinske  fakultet, Universitetet i Oslo.</p></p></div><div id="i42183" class="altsek1"><h1  id="i42184">Nelarabin</h1>

<p class="altsek1a"><p id="i42185">Sanford M, Lyseng-Williamson KA (2008):  Nelarabine, Drugs 68, 439-447.</p></p>
<p class="altsek1a"><p id="i42186">Buie LW, Epstein SS, Lindley CM (2007):  Nelarabine: a novel purine antimetabolite antineoplastic agent.  Clin Ther 29, 1887-1899.</p></p>
<p class="altsek1a"><p id="i42187">Curbo S, Karlsson A (2006): Nelarabine:  a new purine analog in the treatment of hematologic malignancies.  Rev Recent Clin Trials 1, 185-192.</p></p>
<p class="altsek1a"><p id="i42188">Preparatomtale Atriance (<em>www.legemiddelverket.no</em>).</p></p></div><div id="i42189" class="altsek1"><h1  id="i42190">Nilotinib</h1>

<p class="altsek1a"><p id="i42191">Deininger MW (2008): Nilotinib. Clin  Cancer Res 14, 4027-4031.</p></p>
<p class="altsek1a"><p id="i42192">DeRemer DL, Ustun C, Natarajan K (2008)  Nilotinib: a second-generation tyrosine kinase inhibitor for the  treatment of chronic myelogenous leukemia. Clin Ter 30, 1956-1975.</p></p>
<p class="altsek1a"><p id="i42193">Preparatomtale Tasigna (www.legemiddelverket.no).</p></p>
<p class="altsek1a"><p id="i42194">Dahl, O., Lehne, G., Baksaas, I., Kvaløy,  S. & Christoffersen, T. (red.): Medikamentell kreftbehandling.  Cytostatikaboken 7. utg. Farmakologisk Institutt, Det medisinske  fakultet, Universitetet i Oslo.</p></p></div><div id="i42195" class="altsek1"><h1  id="i42196">Talidomid</h1>

<p class="altsek1a"><p id="i42197">von Lilienfeld-Toal M, Hahn-Ast C, Furkert  K, Hoffmann F, Naumann R, Bargou R, Cook G, Glasmacher A (2008):  A systematic review of phase II trials of thalidomide/dexamethasone  combination therapy in patients with relapsed or refractory multiple myeloma.  Eur J Haematol 81, 247-252. </p></p>
<p class="altsek1a"><p id="i42198">Patel MP, Chanan-Khan AA (2009): The  many lives of thalidomide. Leuk Lymphoma 50, 861-862. </p></p>
<p class="altsek1a"><p id="i42199">Teo SK, Colburn WA, Tracewell WG, Kook  KA, Stirling DI, Jaworsky MS, Scheffler MA, Thomas SD, Laskin OL  (2004): Clinical pharmacokinetics of thalidomide. Clin Pharmacokinet  43, 311-327. </p></p>
<p class="altsek1a"><p id="i42200">Kumar S, Rajkumar SV (2006): Thalidomide  and lenalidomide in the treatment of multiple myeloma. Eur J Cancer  42, 1612-1622.</p></p>
<p class="altsek1a"><p id="i42201">Sleijfer S, Kruit WH, Stoter G (2004):  Thalidomide in solid tumours: the resurrection of an old drug.Eur  J Cancer 40, 2377-2382.</p></p>
<p class="altsek1a"><p id="i42202">Preparatomtale Thalidomide Celgene/Pharmion  (<em>www.legemiddelverket.no</em>)</p></p>
<p class="altsek1a"><p id="i42203">Dahl, O., Lehne, G., Baksaas, I., Kvaløy,  S. & Christoffersen, T. (red.): Medikamentell kreftbehandling.  Cytostatikaboken 7. utg. Farmakologisk Institutt, Det medisinske  fakultet, Universitetet i Oslo.</p></p></div><div id="i42204" class="altsek1"><h1  id="i42205">Trabektedin</h1>

<p class="altsek1a"><p id="i42206">Carter NJ, Keam SJ (2007): Trabectedin:  a review of its use in the management of soft tissue sarcoma and  ovarian cancer. Drugs 67, 2257-2276.</p></p>
<p class="altsek1a"><p id="i42207">Preparatomtale Yondelis (<em>www.legemiddelverket.no)</em></p></p>
<p class="altsek1a"><p id="i42208">Dahl, O., Lehne, G., Baksaas, I., Kvaløy,  S. & Christoffersen, T. (red.): Medikamentell kreftbehandling.  Cytostatikaboken 7. utg. Farmakologisk Institutt, Det medisinske  fakultet, Universitetet i Oslo.</p></p></div><div id="i42209" class="altsek1"><h1  id="i42210">Vinflunin</h1>

<p class="altsek1a"><p id="i42211">Bennouna J, Delord JP, Campone M, Nguyen  L: Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res.  2008 14: 1625-1632.</p></p>
<p class="altsek1a"><p id="i42212">Yun-San Yip A, Yuen-Yuen Ong E, Chow  LW: Vinflunine: clinical perspectives of an emerging anticancer  agent. Expert Opin Investig Drugs. 2008, 17:583-591. </p></p>
<p class="altsek1a"><p id="i42213">Lobert S, Puozzo C: Pharmacokinetics,  metabolites, and preclinical safety of vinflunine. Semin Oncol.  2008, 35(Suppl 3): S28-33. </p></p>
<p class="altsek1a"><p id="i42214">Preparatomtale Javlor (<em>www.legemiddelverket.no</em>)</p></p></div></div></article></section>
</div>
<footer>
		<div class="revidertDato">Generert: 23.01.2013</div>
		<h1>Foreningen for utgivelse av Norsk legemiddelhåndbok</h1>
		<address>Postboks 63 Kalbakken - 0901 OSLO - <a href="http://maps.google.com/maps/place?cid=5501084847365814678&q=Sven+Oftedals+vei+8&sll=59.925912,10.801613&sspn=0.036525,0.115218&ie=UTF8&ll=59.965151,10.745831&spn=0.000086,0.000172&t=m&z=13&vpsrc=0" targe="_blank">Besøksadresse: Sven Oftedals vei 8</a></address>
		<address>Telefon: 22 16 84 90 - telefaks: 22 16 84 99 - <a href="mailto:post@legemiddelhandboka.no">E-post: post@legemiddelhandboka.no</a></address>
	</footer>
</div>

</body>
</html>